| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 29 | 2024 | 551 | 7.860 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 21 | 2024 | 240 | 6.970 |
Why?
|
| Biomarkers, Tumor | 12 | 2024 | 207 | 4.090 |
Why?
|
| Autoantibodies | 5 | 2021 | 82 | 1.880 |
Why?
|
| Multiple Pulmonary Nodules | 3 | 2022 | 11 | 1.780 |
Why?
|
| Insulin-Like Growth Factor I | 6 | 2024 | 59 | 1.380 |
Why?
|
| Biomarkers | 9 | 2024 | 559 | 1.260 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2017 | 218 | 1.110 |
Why?
|
| Immunoassay | 3 | 2018 | 38 | 1.080 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 3 | 2015 | 10 | 0.950 |
Why?
|
| Body Composition | 2 | 2024 | 69 | 0.920 |
Why?
|
| Solitary Pulmonary Nodule | 2 | 2015 | 14 | 0.890 |
Why?
|
| Prognosis | 10 | 2024 | 804 | 0.880 |
Why?
|
| Adenocarcinoma | 5 | 2018 | 140 | 0.870 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2020 | 68 | 0.870 |
Why?
|
| Humans | 48 | 2024 | 27158 | 0.860 |
Why?
|
| Neoplasm Staging | 7 | 2024 | 368 | 0.790 |
Why?
|
| Middle Aged | 21 | 2024 | 9031 | 0.780 |
Why?
|
| Immunotherapy | 2 | 2024 | 59 | 0.750 |
Why?
|
| Early Detection of Cancer | 5 | 2022 | 104 | 0.730 |
Why?
|
| Aged | 21 | 2024 | 9084 | 0.730 |
Why?
|
| Cachexia | 2 | 2019 | 12 | 0.700 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 16 | 0.700 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2019 | 36 | 0.690 |
Why?
|
| Aged, 80 and over | 13 | 2024 | 4831 | 0.690 |
Why?
|
| Female | 25 | 2024 | 15269 | 0.660 |
Why?
|
| Male | 24 | 2024 | 14821 | 0.650 |
Why?
|
| HLA Antigens | 2 | 2021 | 14 | 0.640 |
Why?
|
| Algorithms | 7 | 2022 | 352 | 0.630 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2020 | 11 | 0.630 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2018 | 6 | 0.590 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2018 | 15 | 0.580 |
Why?
|
| Syndecan-1 | 1 | 2018 | 5 | 0.580 |
Why?
|
| Vimentin | 2 | 2016 | 2 | 0.580 |
Why?
|
| Neovascularization, Pathologic | 2 | 2015 | 36 | 0.580 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 67 | 0.560 |
Why?
|
| Nerve Growth Factors | 1 | 2018 | 38 | 0.560 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 35 | 0.530 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2013 | 20 | 0.520 |
Why?
|
| Lymphatic Metastasis | 3 | 2012 | 93 | 0.510 |
Why?
|
| Kidney Transplantation | 2 | 2016 | 119 | 0.510 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 245 | 0.510 |
Why?
|
| Cytokines | 2 | 2014 | 233 | 0.470 |
Why?
|
| Graft Rejection | 2 | 2016 | 69 | 0.460 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2014 | 10 | 0.460 |
Why?
|
| Predictive Value of Tests | 5 | 2014 | 478 | 0.450 |
Why?
|
| Adult | 12 | 2018 | 7918 | 0.450 |
Why?
|
| Doxazosin | 1 | 2013 | 1 | 0.430 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2013 | 1 | 0.430 |
Why?
|
| Chloroquine | 1 | 2013 | 7 | 0.430 |
Why?
|
| Melanins | 1 | 2013 | 7 | 0.430 |
Why?
|
| Cohort Studies | 7 | 2024 | 1901 | 0.430 |
Why?
|
| Immunoglobulin G | 3 | 2022 | 80 | 0.430 |
Why?
|
| Sulfonamides | 1 | 2013 | 44 | 0.420 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 11 | 0.410 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 331 | 0.400 |
Why?
|
| Immunoglobulin M | 2 | 2022 | 12 | 0.390 |
Why?
|
| C-Peptide | 1 | 2011 | 5 | 0.380 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 485 | 0.370 |
Why?
|
| Retrospective Studies | 7 | 2019 | 3546 | 0.370 |
Why?
|
| Cell Line, Tumor | 7 | 2020 | 264 | 0.370 |
Why?
|
| Blood Chemical Analysis | 1 | 2010 | 17 | 0.350 |
Why?
|
| Hematologic Tests | 1 | 2010 | 6 | 0.340 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 11 | 0.340 |
Why?
|
| Survival Analysis | 3 | 2021 | 261 | 0.340 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2020 | 55 | 0.340 |
Why?
|
| ErbB Receptors | 4 | 2020 | 55 | 0.330 |
Why?
|
| Area Under Curve | 4 | 2014 | 64 | 0.320 |
Why?
|
| Lymph Nodes | 1 | 2009 | 73 | 0.300 |
Why?
|
| Disease-Free Survival | 3 | 2017 | 179 | 0.300 |
Why?
|
| Treatment Outcome | 6 | 2024 | 3525 | 0.290 |
Why?
|
| Risk Assessment | 4 | 2017 | 628 | 0.280 |
Why?
|
| Body Weight | 3 | 2024 | 135 | 0.280 |
Why?
|
| Antigens, Neoplasm | 2 | 2021 | 41 | 0.260 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 347 | 0.240 |
Why?
|
| Gene Expression Profiling | 2 | 2024 | 143 | 0.240 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 57 | 0.240 |
Why?
|
| Animals | 11 | 2020 | 3625 | 0.240 |
Why?
|
| Proteomics | 2 | 2018 | 88 | 0.220 |
Why?
|
| Young Adult | 4 | 2018 | 2026 | 0.210 |
Why?
|
| Chondrocytes | 3 | 2014 | 151 | 0.210 |
Why?
|
| ROC Curve | 2 | 2014 | 141 | 0.210 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 673 | 0.210 |
Why?
|
| Pneumonectomy | 2 | 2017 | 77 | 0.210 |
Why?
|
| Prospective Studies | 3 | 2024 | 1783 | 0.210 |
Why?
|
| Survival Rate | 2 | 2018 | 344 | 0.210 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2016 | 165 | 0.200 |
Why?
|
| Mutation | 3 | 2020 | 350 | 0.200 |
Why?
|
| Vaccines | 1 | 2022 | 9 | 0.200 |
Why?
|
| Immunoglobulin E | 1 | 2022 | 11 | 0.200 |
Why?
|
| Immunoglobulin A | 1 | 2022 | 14 | 0.200 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2024 | 124 | 0.200 |
Why?
|
| Complement C1q | 1 | 2022 | 9 | 0.200 |
Why?
|
| Sarcopenia | 2 | 2019 | 31 | 0.190 |
Why?
|
| Seroconversion | 1 | 2022 | 1 | 0.190 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2022 | 5 | 0.190 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 17 | 0.190 |
Why?
|
| Body Mass Index | 1 | 2024 | 461 | 0.190 |
Why?
|
| Organoids | 1 | 2021 | 7 | 0.190 |
Why?
|
| Precision Medicine | 1 | 2021 | 28 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 667 | 0.180 |
Why?
|
| Neoplasms | 2 | 2021 | 241 | 0.180 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 1802 | 0.180 |
Why?
|
| Neoplasm Invasiveness | 3 | 2017 | 93 | 0.180 |
Why?
|
| Bone Morphogenetic Protein 7 | 2 | 2011 | 30 | 0.180 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 8 | 0.180 |
Why?
|
| Pilot Projects | 1 | 2022 | 415 | 0.180 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 350 | 0.180 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 18 | 0.180 |
Why?
|
| Observer Variation | 1 | 2021 | 97 | 0.170 |
Why?
|
| Endothelin-1 | 1 | 2020 | 3 | 0.170 |
Why?
|
| Disease Progression | 2 | 2014 | 672 | 0.170 |
Why?
|
| Biochemistry | 1 | 2000 | 1 | 0.170 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 111 | 0.170 |
Why?
|
| Mass Screening | 1 | 2022 | 173 | 0.170 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 324 | 0.170 |
Why?
|
| Proteins | 1 | 2000 | 64 | 0.170 |
Why?
|
| Weight Loss | 2 | 2019 | 127 | 0.160 |
Why?
|
| Receptors, CXCR | 1 | 2019 | 1 | 0.160 |
Why?
|
| Esophagectomy | 1 | 2019 | 23 | 0.160 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2019 | 6 | 0.160 |
Why?
|
| Patient Selection | 1 | 2021 | 197 | 0.160 |
Why?
|
| Protein Binding | 3 | 2014 | 126 | 0.160 |
Why?
|
| Esophageal Neoplasms | 1 | 2019 | 50 | 0.150 |
Why?
|
| RNA, Small Untranslated | 1 | 2018 | 1 | 0.150 |
Why?
|
| Channelopathies | 1 | 2018 | 6 | 0.150 |
Why?
|
| CA1 Region, Hippocampal | 1 | 2018 | 9 | 0.150 |
Why?
|
| Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2018 | 11 | 0.150 |
Why?
|
| Cell Movement | 2 | 2016 | 81 | 0.150 |
Why?
|
| Carcinoma, Large Cell | 1 | 2018 | 12 | 0.150 |
Why?
|
| Transcriptome | 3 | 2024 | 89 | 0.150 |
Why?
|
| Pyramidal Cells | 1 | 2018 | 35 | 0.150 |
Why?
|
| Neuronal Plasticity | 1 | 2018 | 48 | 0.140 |
Why?
|
| SOS1 Protein | 1 | 2016 | 4 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2016 | 12 | 0.130 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2016 | 15 | 0.130 |
Why?
|
| Kidney Tubules | 1 | 2016 | 6 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 172 | 0.130 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2016 | 42 | 0.130 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 65 | 0.130 |
Why?
|
| Cattle | 2 | 2013 | 124 | 0.130 |
Why?
|
| Metformin | 1 | 2016 | 17 | 0.130 |
Why?
|
| Muscle, Skeletal | 1 | 2019 | 383 | 0.130 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 37 | 0.130 |
Why?
|
| Computational Biology | 2 | 2014 | 21 | 0.120 |
Why?
|
| Aggrecans | 2 | 2013 | 54 | 0.120 |
Why?
|
| Cognition | 1 | 2024 | 1337 | 0.120 |
Why?
|
| Mice, Transgenic | 4 | 2019 | 221 | 0.120 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2015 | 2 | 0.120 |
Why?
|
| Risk Factors | 3 | 2024 | 2334 | 0.120 |
Why?
|
| Repressor Proteins | 1 | 2015 | 38 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2011 | 59 | 0.120 |
Why?
|
| Collagen Type X | 1 | 2014 | 3 | 0.120 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 127 | 0.120 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2015 | 52 | 0.120 |
Why?
|
| Minnesota | 1 | 2014 | 6 | 0.120 |
Why?
|
| Mice | 5 | 2020 | 1414 | 0.110 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 19 | 0.110 |
Why?
|
| Microspheres | 1 | 2014 | 25 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2014 | 135 | 0.110 |
Why?
|
| Metabolic Syndrome | 1 | 2014 | 58 | 0.110 |
Why?
|
| Choroid | 1 | 2013 | 1 | 0.110 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2013 | 1 | 0.110 |
Why?
|
| Iris | 1 | 2013 | 2 | 0.110 |
Why?
|
| Biological Assay | 1 | 2013 | 7 | 0.110 |
Why?
|
| Illinois | 1 | 2014 | 250 | 0.110 |
Why?
|
| Reference Values | 1 | 2014 | 185 | 0.110 |
Why?
|
| src-Family Kinases | 1 | 2013 | 7 | 0.110 |
Why?
|
| Collagen Type IV | 2 | 2004 | 4 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2014 | 214 | 0.110 |
Why?
|
| In Vitro Techniques | 1 | 2013 | 166 | 0.110 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 272 | 0.100 |
Why?
|
| Chondroitin Sulfates | 1 | 2013 | 6 | 0.100 |
Why?
|
| Chemokine CCL3 | 1 | 2013 | 8 | 0.100 |
Why?
|
| Cell Proliferation | 3 | 2021 | 179 | 0.100 |
Why?
|
| Granuloma | 1 | 2013 | 14 | 0.100 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2013 | 14 | 0.100 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 9 | 0.100 |
Why?
|
| Amino Acid Sequence | 5 | 2015 | 154 | 0.100 |
Why?
|
| Interleukin-10 | 1 | 2013 | 19 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2019 | 928 | 0.100 |
Why?
|
| Interleukin-1beta | 1 | 2013 | 53 | 0.100 |
Why?
|
| Molecular Sequence Data | 5 | 2015 | 192 | 0.100 |
Why?
|
| Respiratory Tract Infections | 1 | 2013 | 25 | 0.100 |
Why?
|
| Interleukin-6 | 1 | 2013 | 75 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 47 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2014 | 425 | 0.100 |
Why?
|
| Pneumonia | 1 | 2013 | 68 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2024 | 78 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 190 | 0.090 |
Why?
|
| Obesity | 1 | 2014 | 309 | 0.090 |
Why?
|
| Animal Experimentation | 1 | 2010 | 3 | 0.090 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 9 | 0.090 |
Why?
|
| Radiography | 1 | 2013 | 617 | 0.090 |
Why?
|
| Serum | 1 | 2010 | 7 | 0.090 |
Why?
|
| Antibodies, Neoplasm | 1 | 2010 | 12 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 177 | 0.080 |
Why?
|
| Intervertebral Disc | 1 | 2010 | 120 | 0.080 |
Why?
|
| Mass Spectrometry | 3 | 2014 | 34 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2010 | 589 | 0.080 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2008 | 2 | 0.080 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2008 | 27 | 0.080 |
Why?
|
| Phosphoproteins | 1 | 2008 | 26 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2009 | 119 | 0.070 |
Why?
|
| Alzheimer Disease | 2 | 2018 | 2115 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 24 | 0.070 |
Why?
|
| Metals | 1 | 2008 | 139 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 144 | 0.070 |
Why?
|
| Cartilage, Articular | 1 | 2011 | 415 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2014 | 446 | 0.060 |
Why?
|
| Melanoma | 2 | 2004 | 58 | 0.060 |
Why?
|
| Hyaluronan Receptors | 1 | 2004 | 5 | 0.060 |
Why?
|
| Metalloproteases | 1 | 2004 | 6 | 0.060 |
Why?
|
| Peptide Fragments | 2 | 2004 | 76 | 0.060 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2024 | 46 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 41 | 0.050 |
Why?
|
| Adolescent | 1 | 2009 | 2179 | 0.050 |
Why?
|
| Glycosylation | 1 | 2022 | 20 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2022 | 18 | 0.050 |
Why?
|
| Proline | 1 | 2002 | 10 | 0.050 |
Why?
|
| Microsatellite Instability | 1 | 2022 | 12 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 21 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 600 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2021 | 11 | 0.050 |
Why?
|
| Fluorescence | 1 | 2021 | 9 | 0.050 |
Why?
|
| Loss of Heterozygosity | 1 | 2021 | 6 | 0.050 |
Why?
|
| Genomics | 1 | 2021 | 64 | 0.040 |
Why?
|
| Biological Availability | 1 | 2020 | 16 | 0.040 |
Why?
|
| Vasoconstriction | 1 | 2020 | 16 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 903 | 0.040 |
Why?
|
| Base Sequence | 2 | 2014 | 106 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2015 | 129 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2024 | 1197 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2015 | 310 | 0.040 |
Why?
|
| beta-Arrestins | 1 | 2019 | 1 | 0.040 |
Why?
|
| Neoplasms, Experimental | 1 | 2019 | 10 | 0.040 |
Why?
|
| Models, Biological | 1 | 2021 | 320 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 37 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 202 | 0.040 |
Why?
|
| Endoplasmic Reticulum | 1 | 2018 | 26 | 0.040 |
Why?
|
| Action Potentials | 1 | 2018 | 85 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 466 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2017 | 63 | 0.030 |
Why?
|
| Time-Lapse Imaging | 1 | 2016 | 5 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 14 | 0.030 |
Why?
|
| A549 Cells | 1 | 2016 | 11 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2017 | 59 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2016 | 15 | 0.030 |
Why?
|
| Fibrosis | 1 | 2016 | 31 | 0.030 |
Why?
|
| Neutrophils | 1 | 2017 | 100 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 105 | 0.030 |
Why?
|
| Atrophy | 1 | 2016 | 87 | 0.030 |
Why?
|
| Graft Survival | 1 | 2016 | 97 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 200 | 0.030 |
Why?
|
| Twist-Related Protein 1 | 1 | 2015 | 3 | 0.030 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2015 | 7 | 0.030 |
Why?
|
| Arginine | 1 | 2015 | 17 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2015 | 37 | 0.030 |
Why?
|
| Cadherins | 1 | 2015 | 34 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 81 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 148 | 0.030 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2014 | 6 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2014 | 9 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 129 | 0.030 |
Why?
|
| Cyclooxygenase 2 | 1 | 2014 | 29 | 0.030 |
Why?
|
| Hypertrophy | 1 | 2014 | 24 | 0.030 |
Why?
|
| Binding Sites | 1 | 2014 | 72 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2014 | 38 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 87 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 84 | 0.030 |
Why?
|
| Cognitive Dysfunction | 1 | 2024 | 1065 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2014 | 50 | 0.030 |
Why?
|
| Wound Healing | 1 | 2015 | 154 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2014 | 166 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2013 | 3 | 0.030 |
Why?
|
| Protein Kinase C beta | 1 | 2013 | 8 | 0.030 |
Why?
|
| Protein Structure, Secondary | 2 | 2004 | 21 | 0.030 |
Why?
|
| Cell Adhesion | 2 | 2004 | 31 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2015 | 164 | 0.030 |
Why?
|
| Ligands | 2 | 2004 | 38 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2013 | 48 | 0.030 |
Why?
|
| Cell Survival | 1 | 2013 | 119 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2013 | 118 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2013 | 147 | 0.030 |
Why?
|
| Reference Standards | 1 | 2013 | 23 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2013 | 89 | 0.030 |
Why?
|
| Oligosaccharides | 1 | 2013 | 17 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2011 | 8 | 0.020 |
Why?
|
| Support Vector Machine | 1 | 2011 | 7 | 0.020 |
Why?
|
| Presenilin-1 | 1 | 2010 | 8 | 0.020 |
Why?
|
| Smad Proteins | 1 | 2010 | 3 | 0.020 |
Why?
|
| Metabolism | 1 | 2010 | 6 | 0.020 |
Why?
|
| Gels | 1 | 2010 | 12 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 23 | 0.020 |
Why?
|
| Nitriles | 1 | 2010 | 14 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2010 | 40 | 0.020 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2010 | 17 | 0.020 |
Why?
|
| Triazoles | 1 | 2010 | 29 | 0.020 |
Why?
|
| Bone Matrix | 1 | 2010 | 19 | 0.020 |
Why?
|
| Models, Animal | 1 | 2010 | 109 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2010 | 110 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 2010 | 54 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2010 | 133 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2010 | 98 | 0.020 |
Why?
|
| tau Proteins | 1 | 2010 | 235 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2010 | 524 | 0.020 |
Why?
|
| Aging | 1 | 2018 | 1550 | 0.020 |
Why?
|
| Caseins | 1 | 2008 | 1 | 0.020 |
Why?
|
| Manganese | 1 | 2008 | 1 | 0.020 |
Why?
|
| Phosphopeptides | 1 | 2008 | 1 | 0.020 |
Why?
|
| Ovalbumin | 1 | 2008 | 6 | 0.020 |
Why?
|
| Aluminum | 1 | 2008 | 9 | 0.020 |
Why?
|
| Iron | 1 | 2008 | 15 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2008 | 25 | 0.020 |
Why?
|
| Titanium | 1 | 2008 | 169 | 0.020 |
Why?
|
| DNA Primers | 1 | 2004 | 51 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2004 | 52 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 2002 | 3 | 0.010 |
Why?
|
| Drug Stability | 1 | 2002 | 3 | 0.010 |
Why?
|
| Biophysical Phenomena | 1 | 2002 | 26 | 0.010 |
Why?
|
| Basement Membrane | 1 | 2002 | 11 | 0.010 |
Why?
|
| Biophysics | 1 | 2002 | 32 | 0.010 |
Why?
|